Tag Archives: Entest BioMedical

‘Adipose-derived’ Stem Cells Could Help Traumatic Brain Injury Patients

Image by cloois via Flickr

Dr. Feng Lin, Director of Research at Bio-Matrix Scientific Group Inc. (OTCBulletinBoard: BMSN) and Entest BioMedical Inc., today stated that he believes that an effective new therapy for “traumatic brain injury” (TBI) using autologous “adipose-derived” stem cells represents a potential cure for TBI. According to Dr. Lin, both Bio-Matrix and Entest BioMedical are now studying the “therapeutic effect of fat stem cells on traumatic brain injury-associated brain ischemia and inflammation and replacement of damaged neurons with neuron cells differentiated from fat cells.” Bio-Matrix Scientific Group Inc. and Entest BioMedical Inc. recently submitted a research summary
Read More…

Entest BioMedical Files Patent Application for Selective Targeting of Stem Cells to Lung Using Photoceutical Devices

New Technology to Increase Efficacy of Adult Stem Cells in COPD Treatment

Entest BioMedical announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.

Steve Josephs, PhD, a Scientific Advisor to the Company stated “that by using photoceutical devices in treating COPD, it is believed stem cells can be focused on areas of the lungs where there is damage. Furthermore, being
Read More…